{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Increased tumor lysis"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Failure of tumor lysis"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Autologous Myeloma Cells"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Increased tumor lysis"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Failure of tumor lysis"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Peripheral blood mononuclear cells"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"We will isolate the CD8+ populations (CD3+CD8+, CD8+CD56+) using the Auto MACS (Miltenyi) and then identify the mechanisms of tumor cell killing by the CD8+ cells obtained pre-transplant (Baseline) and following the third and fourth cellular infusions. We will examine mechanisms of tumor cell killing through NKG2D receptor, major histocompatibility complex (MHC) Class I molecules or through the T cell receptor. We postulate the CD8+ cells obtained from patient's blood will kill tumor cells both via MHC Class I and through the NKG2D receptor.","groups":[{"description":"Infusing Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF)post-Hematopoietic stem cell transplant (HSCT)\n\nEx-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.","id":"OG000","title":"Ex-vivo Expanded Effector Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Autologous myeloma cells were isolated for only 4 study participants. There is no information on the remaining participant provided.","reportingStatus":"POSTED","timeFrame":"Pre-transplant and following the third and fourth cellular infusions.","title":"Determine the Methods of Tumor Cell Killing of the in Vivo CD8+ Cells: Cytotoxicity Assays, Blocking Experiments, Analysis of T-cell Receptor (TCR)","type":"SECONDARY","unitOfMeasure":"Participants"}